Trial Profile
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jul 2018
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Adimmune Corporation
- 12 Jul 2018 Status changed from recruiting to completed.
- 23 Jan 2013 New trial record